Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of imetelstat versus best available therapy in JAK inhibitor-refractory myelofibrosis
MOH_2021-02-22_009778Phase 3Not yet recruiting
- Sponsor
- Geron Corporation
- Start
- Nov 2020
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imetelstat in myelofibrosis (MF) (2 arms), sponsored by Geron Corporation. Primary endpoint: Overall survival. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
imetelstat
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on MOH_2021-02-22_009778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-02-22_009778.